Cargando…

Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden

In follicular lymphoma (FL), progression of disease ≤24 months (POD24) has emerged as an important prognostic marker for overall survival (OS). We aimed to investigate survival more broadly by timing of progression and treatment in a national population-based setting. We identified 948 stage II-IV i...

Descripción completa

Detalles Bibliográficos
Autores principales: Weibull, Caroline E., Wästerlid, Tove, Wahlin, Björn Engelbrekt, Andersson, Per-Ola, Ekberg, Sara, Lockmer, Sandra, Enblad, Gunilla, Crowther, Michael J., Kimby, Eva, Smedby, Karin E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953041/
https://www.ncbi.nlm.nih.gov/pubmed/36844185
http://dx.doi.org/10.1097/HS9.0000000000000838
_version_ 1784893779511083008
author Weibull, Caroline E.
Wästerlid, Tove
Wahlin, Björn Engelbrekt
Andersson, Per-Ola
Ekberg, Sara
Lockmer, Sandra
Enblad, Gunilla
Crowther, Michael J.
Kimby, Eva
Smedby, Karin E.
author_facet Weibull, Caroline E.
Wästerlid, Tove
Wahlin, Björn Engelbrekt
Andersson, Per-Ola
Ekberg, Sara
Lockmer, Sandra
Enblad, Gunilla
Crowther, Michael J.
Kimby, Eva
Smedby, Karin E.
author_sort Weibull, Caroline E.
collection PubMed
description In follicular lymphoma (FL), progression of disease ≤24 months (POD24) has emerged as an important prognostic marker for overall survival (OS). We aimed to investigate survival more broadly by timing of progression and treatment in a national population-based setting. We identified 948 stage II-IV indolent FL patients in the Swedish Lymphoma Register diagnosed 2007–2014 who received first-line systemic therapy, followed through 2020. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated by first POD at any time during follow-up using Cox regression. OS was predicted by POD using an illness-death model. During a median follow-up of 6.1 years (IQR: 3.5–8.4), 414 patients experienced POD (44%), of which 270 (65%) occurred ≤24 months. POD was represented by a transformation in 15% of cases. Compared to progression-free patients, POD increased all-cause mortality across treatments, but less so among patients treated with rituximab(R)-single (HR = 4.54, 95% CI: 2.76-7.47) than R-chemotherapy (HR = 8.17, 95% CI: 6.09-10.94). The effect of POD was similar following R-CHOP (HR = 8.97, 95% CI: 6.14-13.10) and BR (HR = 10.29, 95% CI: 5.60-18.91). The negative impact of POD on survival remained for progressions up to 5 years after R-chemotherapy, but was restricted to 2 years after R-single. After R-chemotherapy, the 5-year OS conditional on POD occurring at 12, 24, and 60 months was 34%, 46%, and 57% respectively, versus 78%, 82%, and 83% if progression-free. To conclude, POD before but also beyond 24 months is associated with worse survival, illustrating the need for individualized management for optimal care of FL patients.
format Online
Article
Text
id pubmed-9953041
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-99530412023-02-25 Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden Weibull, Caroline E. Wästerlid, Tove Wahlin, Björn Engelbrekt Andersson, Per-Ola Ekberg, Sara Lockmer, Sandra Enblad, Gunilla Crowther, Michael J. Kimby, Eva Smedby, Karin E. Hemasphere Article In follicular lymphoma (FL), progression of disease ≤24 months (POD24) has emerged as an important prognostic marker for overall survival (OS). We aimed to investigate survival more broadly by timing of progression and treatment in a national population-based setting. We identified 948 stage II-IV indolent FL patients in the Swedish Lymphoma Register diagnosed 2007–2014 who received first-line systemic therapy, followed through 2020. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated by first POD at any time during follow-up using Cox regression. OS was predicted by POD using an illness-death model. During a median follow-up of 6.1 years (IQR: 3.5–8.4), 414 patients experienced POD (44%), of which 270 (65%) occurred ≤24 months. POD was represented by a transformation in 15% of cases. Compared to progression-free patients, POD increased all-cause mortality across treatments, but less so among patients treated with rituximab(R)-single (HR = 4.54, 95% CI: 2.76-7.47) than R-chemotherapy (HR = 8.17, 95% CI: 6.09-10.94). The effect of POD was similar following R-CHOP (HR = 8.97, 95% CI: 6.14-13.10) and BR (HR = 10.29, 95% CI: 5.60-18.91). The negative impact of POD on survival remained for progressions up to 5 years after R-chemotherapy, but was restricted to 2 years after R-single. After R-chemotherapy, the 5-year OS conditional on POD occurring at 12, 24, and 60 months was 34%, 46%, and 57% respectively, versus 78%, 82%, and 83% if progression-free. To conclude, POD before but also beyond 24 months is associated with worse survival, illustrating the need for individualized management for optimal care of FL patients. Lippincott Williams & Wilkins 2023-02-23 /pmc/articles/PMC9953041/ /pubmed/36844185 http://dx.doi.org/10.1097/HS9.0000000000000838 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Weibull, Caroline E.
Wästerlid, Tove
Wahlin, Björn Engelbrekt
Andersson, Per-Ola
Ekberg, Sara
Lockmer, Sandra
Enblad, Gunilla
Crowther, Michael J.
Kimby, Eva
Smedby, Karin E.
Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden
title Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden
title_full Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden
title_fullStr Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden
title_full_unstemmed Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden
title_short Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden
title_sort survival by first-line treatment type and timing of progression among follicular lymphoma patients: a national population-based study in sweden
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953041/
https://www.ncbi.nlm.nih.gov/pubmed/36844185
http://dx.doi.org/10.1097/HS9.0000000000000838
work_keys_str_mv AT weibullcarolinee survivalbyfirstlinetreatmenttypeandtimingofprogressionamongfollicularlymphomapatientsanationalpopulationbasedstudyinsweden
AT wasterlidtove survivalbyfirstlinetreatmenttypeandtimingofprogressionamongfollicularlymphomapatientsanationalpopulationbasedstudyinsweden
AT wahlinbjornengelbrekt survivalbyfirstlinetreatmenttypeandtimingofprogressionamongfollicularlymphomapatientsanationalpopulationbasedstudyinsweden
AT anderssonperola survivalbyfirstlinetreatmenttypeandtimingofprogressionamongfollicularlymphomapatientsanationalpopulationbasedstudyinsweden
AT ekbergsara survivalbyfirstlinetreatmenttypeandtimingofprogressionamongfollicularlymphomapatientsanationalpopulationbasedstudyinsweden
AT lockmersandra survivalbyfirstlinetreatmenttypeandtimingofprogressionamongfollicularlymphomapatientsanationalpopulationbasedstudyinsweden
AT enbladgunilla survivalbyfirstlinetreatmenttypeandtimingofprogressionamongfollicularlymphomapatientsanationalpopulationbasedstudyinsweden
AT crowthermichaelj survivalbyfirstlinetreatmenttypeandtimingofprogressionamongfollicularlymphomapatientsanationalpopulationbasedstudyinsweden
AT kimbyeva survivalbyfirstlinetreatmenttypeandtimingofprogressionamongfollicularlymphomapatientsanationalpopulationbasedstudyinsweden
AT smedbykarine survivalbyfirstlinetreatmenttypeandtimingofprogressionamongfollicularlymphomapatientsanationalpopulationbasedstudyinsweden